Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel – Times of India

Aurigene Oncology lab (Picture credit: Aurigene Oncology Limited) HYDERABAD: Dr Reddy’s Laboratories’ wholly-owned subsidiary, Aurigene Oncology Limited, has received Drugs Controller General of India (DCGI) approval for conducting a phase-2…

Continue ReadingAurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel – Times of India

Dr Reddy’s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir – Times of India

Dr Reddy’s Laboratories HYDERABAD: Dr Reddy’s Laboratories and Hetero are among half a dozen generic drug makers to have entered into non-exclusive, royalty-free voluntary licencing agreements with Gilead Sciences Ireland…

Continue ReadingDr Reddy’s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir – Times of India